
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson is well positioned fundamentally because its post-divestiture portfolio is concentrated in higher-quality Innovative Medicine and MedTech businesses, with the former showing broad-based momentum across 28 billion-dollar platforms and the latter expected to recover as procedure trends normalize. Its growth is being driven by powerful launches and franchises such as Tremfya, Darzalex, Tecvayli, Icotyde, and Inlexzo, while 2Q 2026 sales of $25.3Bn and EPS of $2.90, plus raised 2026 guidance to $100.8Bn-$101.4Bn and $11.60-$11.75, underscore execution. The outlook is further supported by diversified U.S.-led revenue, strong cash generation, and management’s confidence in double-digit growth by the end of the decade, giving it resilience against product roll-offs and litigation noise.
Bears say
Johnson & Johnson is facing a negative outlook because its growth depends heavily on newer launches and pipeline catalysts that could disappoint, including Inlexzo, Icotyde, Rybrevant, Caplyta, and TAR-210, while Stelara continues to decline under biosimilar pressure. The company also posted a Q2'26 MedTech miss, with revenue of $8.93B versus $8.99B consensus and 3.7% y/y operational growth, underscoring that even its diversified platform is not insulated from execution risk. Beyond product and operational uncertainty, U.S. drug pricing reform, pharmaceutical tariffs, changes to direct-to-consumer advertising, and ongoing talc and other product-liability litigation create meaningful earnings, valuation, and volatility risk.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares